Literature DB >> 8105834

Synthetic peptide analogs of intercellular adhesion molecule 1 (ICAM-1) inhibit HIV-1 replication in MT-2 cells.

J V Fecondo1, N C Pavuk, K A Silburn, D M Read, A S Mansell, A W Boyd, D A McPhee.   

Abstract

On the basis of reports demonstrating possible roles for leukocyte function-associated antigen 1 (LFA-1) and intercellular adhesion molecule 1 (ICAM-1), the ligand for LFA-1, in human immunodeficiency virus type 1 (HIV-1) infection, we have explored the involvement of the ICAM-1 molecule by using selected synthetic peptides derived from the protein sequence. Replication was assessed in MT-2 cells, highly susceptible to HIV infection, in the presence of four synthetic peptides derived from the ICAM-1 amino acid sequence. This cell type was chosen for the ability to form marked syncytia on infection with cell-free virus. Under the conditions used, minimal or no cytotoxicity was observed with the peptides up to concentrations of 50 micrograms/ml. A peptide corresponding to a unique region of ICAM-1, JF9 [ICAM-1(367-394, A-378)], had little effect on virus replication despite its ability to inhibit cell-cell adhesion. In contrast, an N-terminal peptide, JF7B [ICAM-1(1-23)], consistently inhibited virus replication in MT-2 cells in a dose-dependent manner, as measured by cell-free reverse transcriptase (RT) activity (up to 70% inhibition), soluble virus antigen production (up to 60% inhibition), and syncytium formation (virtually complete inhibition up to 6 days post infection). Testing of W-CAM-1 antibody, and anti-ICAM-1 antibody that inhibits cell-cell adhesion, revealed no significant inhibitory effects on RT activity, virus antigen production, and syncytium formation in HIV-1-infected MT-2 cells at a level that markedly inhibited cell-cell adhesion (10 micrograms/ml).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8105834     DOI: 10.1089/aid.1993.9.733

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  11 in total

1.  Host cell antigenic profile acquired by HIV-1 is a marker of its cellular origin.

Authors:  I Abbate; M R Capobianchi; S Fais; C Castilletti; F Mercuri; P Cordiali Fei; F Ameglio; F Dianzani
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

2.  Inhibition of the adherence of T-lymphocytes to epithelial cells by a cyclic peptide derived from inserted domain of lymphocyte function-associated antigen-1.

Authors:  H Yusuf-Makagiansar; I T Makagiansar; T J Siahaan
Journal:  Inflammation       Date:  2001-06       Impact factor: 4.092

3.  Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization.

Authors:  C D Rizzuto; J G Sodroski
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

4.  Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity.

Authors:  J F Fortin; R Cantin; G Lamontagne; M Tremblay
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

5.  Human T-cell lymphotropic virus type 1 (HTLV-1)-induced syncytium formation mediated by vascular cell adhesion molecule-1: evidence for involvement of cell adhesion molecules in HTLV-1 biology.

Authors:  J E Hildreth; A Subramanium; R A Hampton
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 replication in dendritic cell-T-cell cocultures is increased upon incorporation of host LFA-1 due to higher levels of virus production in immature dendritic cells.

Authors:  Caroline Gilbert; Réjean Cantin; Corinne Barat; Michel J Tremblay
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

7.  Antibody to ICAM-1 mediates enhancement of HIV-1 infection of human endothelial cells.

Authors:  O Scheglovitova; V Scanio; S Fais; S Papadia; I Abbate; C Castilletti; F Dianzani; M R Capobianchi
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

8.  Human immunodeficiency virus type 1 Nef binds directly to Lck and mitogen-activated protein kinase, inhibiting kinase activity.

Authors:  A Greenway; A Azad; J Mills; D McPhee
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

9.  Mechanism of binding and internalization of ICAM-1-derived cyclic peptides by LFA-1 on the surface of T cells: a potential method for targeted drug delivery.

Authors:  Meagan E Anderson; Teruna J Siahaan
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.200

10.  Structure based antibody-like peptidomimetics.

Authors:  Ramachandran Murali; Mark I Greene
Journal:  Pharmaceuticals (Basel)       Date:  2012-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.